1. MassARRAY determination of somatic oncogenic mutations in solid tumors: Moving forward to personalized medicine
- Author
-
Tania Fleitas kanonnikoff, Gloria Ribas, Andrés Cervantes, Maider Ibarrola-Villava, and Anne Bowcock
- Subjects
0301 basic medicine ,Somatic cell ,Concordance ,Computational biology ,medicine.disease_cause ,Bioinformatics ,03 medical and health sciences ,0302 clinical medicine ,Neoplasms ,Medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Cancer biology ,Personalized therapy ,Precision Medicine ,Oligonucleotide Array Sequence Analysis ,Mutation ,business.industry ,High-Throughput Nucleotide Sequencing ,General Medicine ,Oncogenes ,Precision medicine ,030104 developmental biology ,Oncology ,030220 oncology & carcinogenesis ,Personalized medicine ,business - Abstract
This article will review the impact of the recently developed MassARRAY technology on our understanding of cancer biology and treatment. Analysis of somatic mutations is a useful tool in selecting personalized therapy, and for predicting the outcome of many solid tumors. Here, we review the literature on the application of MassARRAY technology (Sequenom Hamburg, Germany) to determine the mutation profile of solid tumors from patients. We summarize the use of commercially available panels of mutations - such as OncoCarta™ or other combinations - and their concordance with results obtained by using other technologies, such as next generation sequencing.
- Published
- 2016